Table of Contents
Lung Cancer International
Volume 2017, Article ID 2782590, 8 pages
https://doi.org/10.1155/2017/2782590
Research Article

Life Expectancy in Pleural and Peritoneal Mesothelioma

Life Expectancy Project, San Francisco, CA, USA

Correspondence should be addressed to Robert Shavelle; gro.ycnatcepxeefil@ellevahs

Received 9 November 2016; Revised 22 December 2016; Accepted 10 January 2017; Published 23 January 2017

Academic Editor: Akira Iyoda

Copyright © 2017 Robert Shavelle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Mesothelioma, http://www.medicinenet.com/mesothelioma/article.htm.
  2. What are the key statistics about malignant mesothelioma?, http://www.cancer.org/cancer/malignantmesothelioma/detailedguide/malignant-mesothelioma-key-statistics.
  3. J. C. McDonald and A. D. McDonald, “The epidemiology of mesothelioma in historical context,” European Respiratory Journal, vol. 9, no. 9, pp. 1932–1942, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Plato, J. I. Martinsen, P. Sparén, G. Hillerdal, and E. Weiderpass, “Occupation and mesothelioma in Sweden: updated incidence in men and women in the 27 years after the asbestos ban,” Epidemiology and Health, vol. 38, Article ID e2016039, 2016. View at Publisher · View at Google Scholar
  5. V. L. Roggli, A. Sharma, K. J. Butnor, T. Sporn, and R. T. Vollmer, “Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases,” Ultrastructural Pathology, vol. 26, no. 2, pp. 55–65, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. J. T. Hodgson and A. Darnton, “The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure,” Annals of Occupational Hygiene, vol. 44, no. 8, pp. 565–601, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. Malignant mesothelioma risk factors, http://www.cancer.org/cancer/malignantmesothelioma/detailedguide/malignant-mesothelioma-risk-factors.
  8. J. G. Edwards, K. R. Abrams, J. N. Leverment, T. J. Spyt, D. A. Waller, and K. J. O'Byrne, “Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems,” Thorax, vol. 55, no. 9, pp. 731–735, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. S. E. Haber and J. M. Haber, “Malignant mesothelioma: a clinical study of 238 cases,” Industrial Health, vol. 49, no. 2, pp. 166–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. Mesothelioma prognosis, http://www.mesotheliomahelp.org/mesothelioma/prognosis/.
  11. K. Inai, “Pathology of mesothelioma,” Environmental Health and Preventive Medicine, vol. 13, no. 2, pp. 60–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Anttila, “Malignant mesothelioma: pathology,” in Occupational Cancers, S. Anttila and P. Boffetta, Eds., chapter 16, pp. 285–298, Springer, London, UK, 2014. View at Publisher · View at Google Scholar
  13. V. M. Rusch, “A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group,” Chest, vol. 108, no. 4, pp. 1122–1128, 1995. View at Publisher · View at Google Scholar
  14. E. G. Butchart, T. Ashcroft, W. C. Barnsley, and M. P. Holden, “Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients,” Thorax, vol. 31, no. 1, pp. 15–24, 1976. View at Publisher · View at Google Scholar · View at Scopus
  15. D. J. Sugarbaker, G. M. Strauss, T. J. Lynch et al., “Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma,” Journal of Clinical Oncology, vol. 11, no. 6, pp. 1172–1178, 1993. View at Google Scholar · View at Scopus
  16. K. Gemba, N. Fujimoto, K. Aoe et al., “Treatment and survival analyses of malignant mesothelioma in Japan,” Acta Oncologica, vol. 52, no. 4, pp. 803–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. W. T. Vigneswaran, D. Y. Kircheva, V. Ananthanarayanan et al., “Amount of epithelioid differentiation is a predictor of survival in malignant pleural mesothelioma,” The Annals of Thoracic Surgery, 2016. View at Publisher · View at Google Scholar
  18. E. Taioli, A. S. Wolf, M. Camacho-Rivera et al., “Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) Study of 14,228 Patients,” PLoS ONE, vol. 10, no. 12, article no. A922, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. T. Milano and H. Zhang, “Malignant pleural mesothelioma: a population-based study of survival,” Journal of Thoracic Oncology, vol. 5, no. 11, pp. 1841–1848, 2010. View at Publisher · View at Google Scholar
  20. F. Baumann, E. Flores, A. Napolitano et al., “Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival,” Carcinogenesis, vol. 36, no. 1, pp. 76–81, 2015. View at Publisher · View at Google Scholar
  21. D. Mirabelli, S. Roberti, M. Gangemi et al., “Survival of peritoneal malignant mesothelioma in Italy: A Population-based Study,” International Journal of Cancer, vol. 124, no. 1, pp. 194–200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Faig, S. Howard, E. A. Levine, G. Casselman, M. Hesdorffer, and J. A. Ohar, “Changing pattern in malignant mesothelioma survival,” Translational Oncology, vol. 8, no. 1, pp. 35–39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. T. D. Yan, M. Deraco, D. Baratti et al., “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience,” Journal of Clinical Oncology, vol. 27, no. 36, pp. 6237–6242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. G. H. Eltabbakh, M. S. Piver, R. E. Hempling, F. O. Recio, and M. E. Intengen, “Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma,” Journal of Surgical Oncology, vol. 70, no. 1, pp. 6–12, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. S. J. Gould, The median isn't the message, Discover Magazine, June 1985.
  26. SEER Reference Surveillance, Epidemiology, and End Results (SEER) Program, SEER∗Stat Database: Incidence—SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973–2011 varying)—Linked To County Attributes—Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, https://seer.cancer.gov/.
  27. D. Collett, Modelling Survival Data in Medical Research, Chapman and Hall, London, UK, 1994.
  28. SAS Institute, SAS Version 9.4, SAS Institute, Cary, NC, USA, 2016.
  29. V. K. Rohatgi, An Introduction to Probability Theory and Mathematical Statistics, John Wiley & Sons, New York, NY, USA, 1976. View at MathSciNet
  30. E. Arias, United States Life Tables, 2010. National Vital Statistics Reports, vol. 63, no. 7, National Center for Health Statistics, Hyattsville, Md, USA, 2014.
  31. G. Pasello, G. L. Ceresoli, and A. Favaretto, “An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma,” Cancer Treatment Reviews, vol. 39, no. 1, pp. 10–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. F. Muers, R. J. Stephens, P. Fisher et al., “Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial,” The Lancet, vol. 371, no. 9625, pp. 1685–1694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Hubert, E. Thiboutot, P. Dubé, A.-S. Cloutier, P. Drolet, and L. Sideris, “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis,” Surgical Oncology, vol. 24, no. 1, pp. 41–46, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. H. R. Alexander Jr., D. L. Bartlett, J. F. Pingpank et al., “Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma,” Surgery, vol. 153, no. 6, pp. 779–786, 2013. View at Publisher · View at Google Scholar · View at Scopus